|
|
Volumn 5, Issue 6, 2006, Pages 285-288
|
|
A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEFACEPT;
BIOLOGICAL RESPONSE MODIFIER;
CYCLOSPORIN;
DERMATOLOGICAL AGENT;
EFALIZUMAB;
ETRETIN;
HYBRID PROTEIN;
IMMUNOGLOBULIN G;
METHOTREXATE;
MONOCLONAL ANTIBODY;
TNFR FC FUSION PROTEIN;
TNFR-FC FUSION PROTEIN;
TUMOR NECROSIS FACTOR RECEPTOR;
DRUG ADMINISTRATION;
HOSPITALIZATION;
HUMAN;
ORAL DRUG ADMINISTRATION;
PATHOLOGY;
PSORIASIS;
REVIEW;
ACITRETIN;
ADMINISTRATION, ORAL;
ANTIBODIES, MONOCLONAL;
BIOLOGICAL RESPONSE MODIFIERS;
CYCLOSPORINE;
DERMATOLOGIC AGENTS;
DRUG ADMINISTRATION SCHEDULE;
HUMANS;
IMMUNOGLOBULIN G;
METHOTREXATE;
PSORIASIS;
RECEPTORS, TUMOR NECROSIS FACTOR;
RECOMBINANT FUSION PROTEINS;
SEVERITY OF ILLNESS INDEX;
|
|
EID: 34347238995
PISSN: 15409740
EISSN: None
Source Type: Journal
DOI: 10.1111/j.1540-9740.2006.05679.x Document Type: Review |
|
Times cited : (18)
|
|
References (20)
|
